The prevalence of XXXX in Iceland.

@entity1 @entity227 @entity1538 @entity9998 @entity726
A compilation of all prescriptions issued for @entity726 medication in Iceland for a 6 months period, together with hospital records of all @entity1 operated on for primary @entity1538 but not on @entity726 medication, were analysed for the prevalence and distribution of @entity726 in Iceland. The @entity726 population consisted of 1916 individuals (991 males and 925 females), amounting to an overall prevalence of 8.3 per thousand population. About 80% of the @entity1 were on @entity726 medication and the remaining had been operated on but had not used drugs. Only 2.6% of the @entity726 population was under 50 years of age. The overall prevalence among those aged 50 and older was 35.3 per 1000, all having primary open @entity726 (subsuming @entity726 with @entity9998 ). The prevalence increased with age from 5.7 per 1000 at age 50-59, to 107.5 at age 80 and older. Rates for males were significantly higher than rates for females in all age groups. The rates were highest in regions where ophthalmologists visit health centers regularly. Assuming that the @entity1538 @entity1 in Iceland as a whole have a similar eye status to the @entity1 attending the University Outpatient @entity726 Clinic, the overall prevalence of @entity227 ( @entity227 ) in the population aged 50 and older is 19.1 per thousand. The age specific prevalence of @entity227 in Iceland is therefore consistent with results of prevalence studies in neighbouring countries.
